Sodium phenylacetate/sodium benzoate: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
ClaireLewis (talk | contribs) |
||
| Line 60: | Line 60: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Pediatrics]] | |||
Latest revision as of 22:24, 23 September 2019
Administration
- Type:
- Dosage Forms:
- Routes of Administration: IV
- Common Trade Names: Ammunol
Adult Dosing
- 5.5g/m2 over 90-120min
Pediatric Dosing
Hyperammonemia
- <20kg: 250mg/kg in D10 over 90min; then 250mg/kg/d infusion
- >20kg: 5.5g/m2 over 90-120min
Special Populations
Pregnancy Rating
- Pregnancy Category C
Lactation risk
- Unknown risk
Renal Dosing
- Adult: Monitor closely
- Pediatric: Monitor closely
Hepatic Dosing
- Adult: caution with use
- Pediatric: caution with use
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Hypokalemia
- Fluid overload
- Tissue damage with extravasation from peripheral IV
- Neurotoxicity, seizure, coma
- Hyperventilation with metabolic acidosis (similar to salicylate toxicity)
Common
- Vomiting, hyperglycemia, hypokalemia, convulsions, and mental impairment.
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
